Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Aug 2024
- Primary completion
- May 2028
- Modality
- Molecular Glues
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ITU512 in sickle cell disease (SCD) (6 arms), sponsored by Novartis. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events up to 5 months, Dose discontinued due to Adverse Events up to 30 days and 3 more. Started Aug 2024; status: recruiting.
02
Drugs
ITU512
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06546670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546670.